S&P 500   5,022.21
DOW   37,753.31
QQQ   425.84
ASML Fires Warning Shot For Tech Investors
Checking in with 5 Bitcoin Stocks Ahead of Bitcoin's Halving
Closing prices for crude oil, gold and other commodities
Lululemon’s P/E Is Back to 2017 Levels: Should You Buy the Dip?
Abbott Laboratories Outlook is Healthy: Buy the Dip
Prologis Stock Leading U.S. Logistics Boom
Johnson & Johnson’s Q1 Checkup: Mixed Results, Optimism Remains
S&P 500   5,022.21
DOW   37,753.31
QQQ   425.84
ASML Fires Warning Shot For Tech Investors
Checking in with 5 Bitcoin Stocks Ahead of Bitcoin's Halving
Closing prices for crude oil, gold and other commodities
Lululemon’s P/E Is Back to 2017 Levels: Should You Buy the Dip?
Abbott Laboratories Outlook is Healthy: Buy the Dip
Prologis Stock Leading U.S. Logistics Boom
Johnson & Johnson’s Q1 Checkup: Mixed Results, Optimism Remains
S&P 500   5,022.21
DOW   37,753.31
QQQ   425.84
ASML Fires Warning Shot For Tech Investors
Checking in with 5 Bitcoin Stocks Ahead of Bitcoin's Halving
Closing prices for crude oil, gold and other commodities
Lululemon’s P/E Is Back to 2017 Levels: Should You Buy the Dip?
Abbott Laboratories Outlook is Healthy: Buy the Dip
Prologis Stock Leading U.S. Logistics Boom
Johnson & Johnson’s Q1 Checkup: Mixed Results, Optimism Remains
S&P 500   5,022.21
DOW   37,753.31
QQQ   425.84
ASML Fires Warning Shot For Tech Investors
Checking in with 5 Bitcoin Stocks Ahead of Bitcoin's Halving
Closing prices for crude oil, gold and other commodities
Lululemon’s P/E Is Back to 2017 Levels: Should You Buy the Dip?
Abbott Laboratories Outlook is Healthy: Buy the Dip
Prologis Stock Leading U.S. Logistics Boom
Johnson & Johnson’s Q1 Checkup: Mixed Results, Optimism Remains
OTCMKTS:INNVD

Innovus Pharmaceuticals (INNVD) Stock Price, News & Analysis

Today's Range
N/A
50-Day Range
$3.00
$3.00
52-Week Range
N/A
Volume
4,300 shs
Average Volume
9,592 shs
Market Capitalization
$7.07 million
P/E Ratio
N/A
Dividend Yield
N/A
Price Target
N/A
INNVD stock logo

About Innovus Pharmaceuticals Stock (OTCMKTS:INNVD)

Innovus Pharmaceuticals, Inc., a pharmaceutical company, engages in the development, licensing, and commercialization of non-prescription medicines and consumer care products in the United States. Its products include Zestra, a proprietary blend of essential oils to enhance desire, arousal, and satisfaction in women; EjectDelay, an over-the-counter monograph compliant benzocaine gel for premature ejaculation; Sensum+, a non-medicated cream for penile sensitivity; Zestra Glide, a water-based longer lasting lubricant; Vesele, a proprietary oral supplement for promoting sexual health; and Androferti, a natural supplement to support male reproductive health and sperm quality. The company also offers Beyond Human testosterone booster, ketones, krill oil, omega 3 fish oil, Vision Formula, blood sugar, colon cleanse, green coffee extract, and growth agent; RecalMax for brain health; UriVarx, a supplement for overactive bladder and urinary incontinence; PEVarx, a supplement for peak sexual performance; ProstaGorx, a supplement for prostate support; and FlutiCare, a nasal spray. In addition, its products include Apeaz for pain relief; AllerVarx for allergy relief; ArthriVarx for joint pain; Xyralid, a hemorrhoid cream; Can-C eye drop and eye care capsule; MZS, a melatonin formula to enhance sleep patterns; and Diabasens, a diabetic foot cream. The company's pipeline products comprise UriVarx for urinary tract infection; Xyralid suppositories for hemorrhoidal symptoms; GlucoGorx supplement, glucometer, lancing device, and GlucoGorx strip for blood sugar levels; Vesele and RecalMax nitric oxide strips. It markets and sells its products through commercial partners to primary care physicians, urologists, gynecologists, and therapists, as well as to other healthcare providers; and directly to consumers through online channels, retailers, and wholesalers. Innovus Pharmaceuticals, Inc. was founded in 2008 and is headquartered in San Diego, California.

INNVD Stock News Headlines

The “Perfect Storm” for Gold
Gold has already reached all-time highs, and experts believe it's not slowing down any time soon. In fact, some analysts predict a $7,000 price tag by 2025.
The “Perfect Storm” for Gold
Gold has already reached all-time highs, and experts believe it's not slowing down any time soon. In fact, some analysts predict a $7,000 price tag by 2025.
ELDN Eledon Pharmaceuticals, Inc.
Ampio Pharmaceuticals Up 26% on Securities-Sale Updates
The Analyst Verdict: Regeneron Pharmaceuticals In The Eyes Of 10 Experts
Citius Pharmaceuticals Inc (CTXR)
Apellis Pharmaceuticals Inc (APLS)
TRACON Pharmaceuticals Inc (TCON)
Syros Pharmaceuticals Inc (SYRS)
See More Headlines
Receive INNVD Stock News and Ratings via Email

Sign-up to receive the latest news and ratings for Innovus Pharmaceuticals and its competitors with MarketBeat's FREE daily newsletter.

Company Calendar

Last Earnings
4/01/2019
Today
4/18/2024

Industry, Sector and Symbol

Sector
Medical
Industry
Pharmaceutical Preparations
Sub-Industry
N/A
Current Symbol
OTCMKTS:INNVD
CIK
N/A
Fax
N/A
Employees
12
Year Founded
N/A

Profitability

Net Income
$-8,280,000.00
Pretax Margin
N/A

Debt

Sales & Book Value

Annual Sales
$23.99 million
Book Value
$0.05 per share

Miscellaneous

Free Float
N/A
Market Cap
$7.07 million
Optionable
Not Optionable
Beta
2.89
7 Stocks to Buy And Hold Forever Cover

Click the link below and we'll send you MarketBeat's list of seven stocks and why their long-term outlooks are very promising.

Get This Free Report

Key Executives

  • Dr. Bassam B. Damaj (Age 51)
    Pres, CEO & Director
  • Mr. Ryan J. Selhorn CPA (Age 37)
    VP & CFO
  • Mr. Randy J. Berholtz (Age 58)
    Exec. VP of Corp. Devel., Gen. Counsel & Sec.
  • Mr. Christopher Stella
    VP of Operations
  • Mr. Robert C. Verfurth
    VP of Sales & Marketing

INNVD Stock Analysis - Frequently Asked Questions

How were Innovus Pharmaceuticals' earnings last quarter?

Innovus Pharmaceuticals Inc (OTCMKTS:INNVD) posted its quarterly earnings results on Monday, April, 1st. The company reported ($0.99) earnings per share for the quarter, topping analysts' consensus estimates of ($1.11) by $0.12. The company earned $4.75 million during the quarter, compared to the consensus estimate of $8.13 million. Innovus Pharmaceuticals had a negative trailing twelve-month return on equity of 682.54% and a negative net margin of 34.51%.

How do I buy shares of Innovus Pharmaceuticals?

Shares of INNVD stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services.
Compare Top Brokerages Here.

This page (OTCMKTS:INNVD) was last updated on 4/18/2024 by MarketBeat.com Staff

From Our Partners